Prostatic Cancer Presenting as an Isolated Large Lung Mass

  • No, Hee-Sun (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Lee, Jong-Hwan (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Ahn, Young (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Na, Im-Il (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Kim, Hye-Ryoun (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Kim, Cheol-Hyeon (Department of Internal Medicine, Korea Cancer Center Hospital) ;
  • Koh, Jae-Soo (Department of Pathology, Korea Cancer Center Hospital) ;
  • Lee, Jae-Cheol (Department of Internal Medicine, Korea Cancer Center Hospital)
  • Received : 2009.12.14
  • Accepted : 2009.12.30
  • Published : 2010.05.30


A hidden primary tumor presenting as an isolated lung mass is a diagnostic challenge to physicians because the diagnosis of lung cancer is likely to be made if the histologic findings are not inconsistent with lung cancer. A large lung mass was found incidentally in a 59-year-old man. Although adenocarcinoma was diagnosed by percutaneous needle biopsy, thyroid transcription factor-1 (TTF-1) immunostaining was negative, raising suspicion that there was another primary site. There was no abnormal finding except for the lung mass on a $^{18}FDG$-PET/CT scan and the patient did not complain of any discomfort. Finally, prostatic cancer was confirmed through the study of tumor markers and prostate-specific antigen (PSA) immunostaining. Because of the rare presentation of a single lung mass in malignancies that have another primary site, physicians should carefully review all data before making a final diagnosis of lung cancer.


  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
  2. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45.
  3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578-83.
  4. Fabozzi SJ, Schellhammer PF, el-Mahdi AM. Pulmonary metastases from prostate cancer. Cancer 1995;75:2706-9.<2706::AID-CNCR2820751111>3.0.CO;2-Y
  5. Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P. Chapter 40. Cancers of the genitourinary system. In: Devita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1392-462.
  6. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.<191::AID-CNCR2820751307>3.0.CO;2-Y
  7. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9.
  8. Yamada T, Ono S, Tsuboi M, Saito H, Sato A, Matsuhashi T, et al. Low-dose CT of the thorax in cancer follow-up. Eur J Radiol 2004;51:169-74.
  9. Weng MJ, Wu MT, Pan HB, Kan YY, Yang CF. The feasibility of low-dose CT for pulmonary metastasis in patients with primary gynecologic malignancy. Clin Imaging 2004;28:408-14.
  10. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223-32.
  11. Choi YH, Park KY, Ryoo BY, Na, II, Yang SH, Koh JS, et al. Presence of malignant mesothelial cells in the sputum. Intern Med 2008;47:57-60.
  12. Moldvay J, Jackel M, Bogos K, Soltesz I, Agocs L, Kovacs G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004;10:85-8.
  13. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-8.